For Senior Investigators

The Chaim Roifman Scholar Award for Senior Investigators

Supported by Baxter BioScience, CSL Behring Canada Ltd, Grifols Canada Ltd, Octapharma Canada Inc and Immunodeficiency Canada

Call for Research Proposals

Immunodeficiency Canada each fall annually requests proposals focused on research in primary immune deficiency (PI).


Research objectives should address one or more of the unique needs of patients with primary immunodeficiency:

  • Study the clinical, cellular and molecular characteristics of genetically determined immunodeficiency diseases
  • Discover improved diagnostic tools for PI
  • Advance novel therapeutic approaches for PI
  • Advance education of patients and medical professionals

Eligibility and requirements

Independent investigators from the academic sectors are encouraged to submit their applications.

  • Eligible investigators must have a faculty appointment.
  • Preference will be given to Canadian based researchers or collaborators of Canadian researchers.
  • Principal Investigator must directly supervise the research project.
  • Applications must be submitted by fiscally responsible organizational entities in the name of the Principal Investigator. Each application must include appropriate endorsement of an official who is responsible for the administration of awarded funds.

Value of Award

The award will pay research expenses up to $25,000.

Duration of Grant Support

The duration of support will be for one to two years.


Award Recipient shall acknowledge the support by using the full name of the award in any publication or presentation made during or resulting from the tenure of the award. Immunodeficiency Canada shall similarly be informed of submission of papers for publication which result from the term of this award. The Award Recipient is required to present the research at an Immunodeficiency Canada sponsored event.

Termination of the Award

The Award Recipient, the Institution and/or Immunodeficiency Canada may terminate the Award at any time for good and sufficient reason.

Submission process

  • Applicants will submit a short 1 page Letter of Intent. If approved by the review committee, the applicant will be asked to submit a full application.
  • Full applications are limited to 3 pages of text.

Research Review Criteria

Full applications will be scored similar to the CIHR system based on:

  • Responsiveness to Immunodeficiency Canada objectives
  • Scientific merit including significance, importance, clinical relevance, innovation and feasibility
  • Leadership, expertise, experience, and commitment of the investigator to the field of PI
  • Adequacy of the research environment including laboratories and/or clinical populations
  • Contribution to the development of PI research in Canada

If a full application is not approved, resubmission is permitted.

Immunodeficiency Canada
415 Yonge Street, Suite 1604 ,Toronto, Ontario, M5B 2E7
T: (416) 964-3434
F: (416) 964-6594

How to Apply

There are two steps in applying for this grant:

(A) Letter of Intent
Please complete the above Letter of Intent. and email the form to Canadian Immunodeficiency at  by 5:00PM on Friday September 29, 2017.

(B) Application Package
The full application package is due no later than Friday November 24, 2017. This package  includes the application, a 3 page proposal plus references and figures, detailed budget and CV. All applications should be submitted digitally to

If you have any questions or concerns please feel free to contact us by phone or email. We will be happy to assist you.